Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped ...

Shares in Merck – known outside North America as MSD – tumbled after the drugmaker said it was halting shipments of a top-selling vaccine to China to help a key local supplier reduce excess ...

TD Cowen downgraded Merck (MRK) to Hold from Buy with a price target of $100, down from $121. The firm says its Buy thesis “broke down” with Gardasil’s challenges in China. It is ...

RAHWAY, N.J., January 28, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

COLLINSVILLE, Ill. – The Major Case Squad now believes the MSD worker who was shot and killed in her own driveway Tuesday morning was targeted by a gunman. A team of investigators is now ...

The growing sophistication of tumor molecular profiling has helped to slowly transition oncologic care toward a more personalized approach in different tumor types, including in bladder cancer. The ...

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

Now there’s a new one for the list: cancer prevention vaccines. Merck, which makes the commonly used Gardasil shot, has shed 14 per cent of its market value since announcing last week that it ...

Klaus has also driven strategic partnerships, such as the joint development of Lynparza with Merck/MSD. Earlier in his pharmaceutical industry career, Klaus held senior oncology-focused positions at ...